Effects of polyether-modified poly(acrylic acid) microgels on doxorubicin transport in human intestinal epithelial Caco-2 cell layers

Journal of Controlled Release

Volumn 88, Issue 1, 2003, Pages 11-22

  Bromberg, Lev ^a   Alakhov, Valery ^b  

^a Massachusetts Institute of Technology Cambridge   (United States)

^b Supratek Pharma Inc   (Canada)

Author keywords

Caco 2; Doxorubicin transport; Microgel; Pluronic; Poly(acrylic acid)

Indexed keywords

CARBOMER; COPOLYMER; DOXORUBICIN; ETHER; ETHYLENE OXIDE; GLYCOPROTEIN P; MANNITOL; POLOXAMER; POLYACRYLIC ACID; PROPYLENE OXIDE; UNCLASSIFIED DRUG; VERAPAMIL;

ABSORPTION; ARTICLE; CELL STRAIN CACO 2; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG INHIBITION; DRUG TRANSPORT; ELECTRIC RESISTANCE; GASTROINTESTINAL TRACT; HUMAN; HUMAN CELL; HYDROPHILICITY; HYDROPHOBICITY; INTESTINE EPITHELIUM CELL; MICROGEL; PRIORITY JOURNAL; WEIGHT;

ACRYLIC RESINS; ALGORITHMS; ANTIBIOTICS, ANTINEOPLASTIC; BIOLOGICAL TRANSPORT, ACTIVE; CACO-2 CELLS; CALCIUM CHANNEL BLOCKERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLORIMETRY; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; EPITHELIUM; FLOW CYTOMETRY; GELS; HUMANS; MANNITOL; P-GLYCOPROTEINS; PERMEABILITY; POLOXAMER; SPECTROMETRY, FLUORESCENCE; TIGHT JUNCTIONS; VERAPAMIL;

EID: 0037436029     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(02)00419-4     Document Type: Article

References (58)

1. Malingre M.M., Beijnen J.H., Schellens J.H. Oral delivery of taxanes. Invest. New Drugs. 19:(2):2001;155-162.
2. Torres-Lugo M., Garcia M., Record R., Peppas N.A. pH-Sensitive hydrogels as gastrointestinal tract absorption enhancers: transport mechanisms of salmon calcitonin and other model molecules using the Caco-2 cell model. Biotechnol. Prog. 18:(3):2002;612-616.
3. Pontier C., Viana M., Champion E., Bernache-Assollant D., Chulia D. HT29-MTX and Caco-2/TC7 monolayers as predictive models for human intestinal absorption: role of the mucus layer. J. Pharm. Sci. 90:(10):2001;1608-1619.
4. Hidalgo I.J. Assessing the absorption of new pharmaceuticals. Curr. Top. Med. Chem. 1:(5):2001;385-401.
5. Bromberg L. Novel family of thermogelling materials via C-C bonding between poly(acrylic acid) and poly(ethylene oxide)-b-poly(propylene oxide)-b-poly(ethylene oxide). J. Phys. Chem. B. 102:(11):1998;1956-1963.
6. Bromberg L. Properties of aqueous solutions and gels of pPoly(ethylene oxide)-b-poly(propylene oxide)-b-poly(ethylene oxide)-g-poly(acrylic acid). J. Phys. Chem. B. 102:(52):1998;10736-10744.
7. Bromberg L. Polyether-modified poly(acrylic acid): synthesis and applications. Ind. Eng. Chem. Res. 37:(11):1998;4267-4274.
8. Bromberg L. Synthesis and self-assembly of poly(ethylene oxide)-b-poly(propylene oxide)-b-poly(ethylene oxide)-g-poly(acrylic acid) gels. Ind. Eng. Chem. Res. 40:(11):2001;2437-2444.
9. Bromberg L., Temchenko M., Hatton T.A. Dually responsive microgels from polyether-modified poly(acrylic acid): swelling and drug loading. Langmuir. 18:(22):2002;4944-4952.
10. Bromberg L.E., Orkisz M.J., Ron E.S. Bioadhesive properties of polyoxyethylene-b-polyoxypropylene-b-polyoxyethylene-g-poly(acrylic acid) polymers (Smart Hydrogel™). Polym. Prep. 38:(2):1997;626-627.
11. Bromberg L.E., Ron E.S. Protein and peptide release from temperature-responsive gels and thermogelling polymer matrices. Adv. Drug Deliv. Rev. 31:(3):1998;197-221.
12. Bromberg L.E. Interactions between hydrophobically modified polyelectrolytes and mucin. Polym. Prep. 40:(2):1999;616-617.
13. Bromberg L. Enhanced nasal retention of hydrophobically modified polyelectrolytes. J. Pharm. Pharmacol. 53:(1):2001;109-114.
14. Bromberg L., Temchenko M. Loading of hydrophobic compounds into micellar solutions of hydrophobically modified polyelectrolytes. Langmuir. 15:(25):1999;8627-8632.
15. Bromberg L.E., Barr D.P. Aggregation phenomena in aqueous solutions of hydrophobically modified polyelectrolytes. A probe solubilization study. Macromolecules. 32:(11):1999;3649-3657.
16. Bromberg L. Self-assembly in aqueous solutions of polyether-modified poly(acrylic acid). Langmuir. 14:(20):1998;5806-5812.
17. Bromberg L.E., Temchenko M., Colby R.H. Interactions among hydrophobically modified polyelectrolytes and surfactants of the same charge. Langmuir. 16:(6):2000;2609-2614.
18. Higgins C.F., Callaghan R., Linton K.J., Kosenberg M.F., Ford R.C. Structure of the multidrug resistance P-glycoprotein. Semin. Cancer Biol. 8:1997;135-142.
19. Bellamy W.T. P-glycoproteins and multidrug resistance. Annu. Rev. Pharmacol. Toxicol. 36:1996;161-183.
20. Tran C.D.H., Timmins P., Conway B.R., Irwin W.J. Investigation of the coordinated functional activities of cytochrome P450 3A4 and P-glycoprotein in limiting the absorption of xenobiotics in Caco-2 cells. J. Pharm. Sci. 91:2002;117-128.
21. Lo Y.-L., Huang J.-D. Effects of sodium deoxycholate and sodium caprate on the transport of epirubicin in human intestinal epithelial Caco-2 cell layers and evented gut sacs of rats. Biochem. Pharmacol. 59:2000;665-672.
22. Ho N.F., Burton P.S., Contradi R.A., Barsuhn C.L. A biophysical model of passive and polarized active transport processes in Caco-2 cells: approaches to uncoupling apical and basolateral membrane events in the intact cell. J. Pharm. Sci. 84:1995;21-27.
23. Hunter J., Jepson M.A., Tsuruo T., Simmons N.L., Hirst B.H. Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. Kinetics of vinblastine secretion and interaction with modulators. J. Biol. Chem. 268:1993;14991-14997.
24. Ford J.M., Hait W.N. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol. Rev. 42:1990;155-199.
25. Sparreboom A., van Asperen J., Mayer U., Schinkel A.H., Smit J.W., Meijer D.K., Borst P., Nooijen W.J., Beijnen J.H., van Tellingen O. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc. Natl. Acad. Sci. USA. 94:(5):1997;2031-2035.
26. Lo Y.-L. Phospholipids as multidrug resistance modulators of the transport of epirubicin in human intestinal epithelial Caco-2 cell layers and everted gut sacs of rats. Biochem. Pharmacol. 60:2000;1381-1390.
27. van der Sandt I.C.J., Blom-Roosemalen M.C.M., de Boer A.G., Breimer D.D. Specificity of doxorubicin versus rhodamine-123 in assessing P-glycoprotein functionality in the LLC-PK1, LLC-PK1:MDR1 and Caco-2 cell lines. Eur. J. Pharm. Sci. 11:2000;207-214.
28. Lindmark T., Kimura Y., Artursson P. Absorption enhancement through intracellular regulation of tight junction permeability by medium chain fatty acids in Caco-2 cells. J. Pharmacol. Exp. Ther. 284:1998;362-369.
29. Dudeja P.K., Anderson K.M., Harris J.S., Buckingham L., Coon J.S. Reversal of multidrug resistance phenotype by surfactants: relationship to membrane lipid fluidity. Arch. Biochem. Biophys. 319:1995;309-315.
30. Regev R., Assaraf Y.G., Eytan G.D. Membrane fluidization by ether, other anesthetics, and certain agents abolishes P-glycoprotein ATPase activity and modulates efflux from multidrug-resistant cells. Eur. J. Biochem. 259:1999;18-24.
31. Ambudkar S.V., Dey S., Hrycyna C.A., Ramachandra M., Pastan I., Gottesman M.M. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol. 39:1999;361-398.
32. Nerurkar M.M., Burton P.S., Borchardt R.T. The use of surfactants to enhance the permeability of peptides through Caco-2 cells by inhibition of an apically polarized efflux system. Pharm. Res. 13:1996;528-534.
33. Nerurkar M.M., Ho N.F., Burton P.S., Vidmar T.J., Borchardt R.T. Mechanistic roles of neutral surfactants on concurrent polarized and passive membrane transport of a model peptide in Caco-2 cells. J. Pharm. Sci. 86:1997;813-821.
34. Batrakova E.V., Li S., Miller D.W., Kabanov A.V. Pluronic P85 increases permeability of a broad Spectrum of drugs in polarized BBMEC and Caco-2 cell monolayers. Pharm. Res. 16:(9):1999;1366-1372.
35. Batrakova E.V., Li S., Elmquist W.F., Miller D.W., Alakhov V.Yu., Kabanov A.V. Mechanism of sensitization of MDR cancer cells by Pluronic block copolymers: Selective energy depletion. Br. J. Cancer. 85:(12):2001;1987-1997.
36. Alakhov V., Klinski E., Lemieux P., Pietrzynski G., Kabanov A. Block copolymeric biotransport carriers as versatile vehicles for drug delivery. Expert Opin. Biol. Ther. 1:(4):2001;583-602.
37. Batrakova E.V., Li S., Vinogradov S.V., Alakhov V.Yu., Miller D.W., Kabanov A.V. Mechanism of pluronic effect on P-glycoprotein efflux system in blood-brain barrier: contributions of energy depletion and membrane fluidization. J. Pharmacol. Exp. Ther. 299:(2):2001;483-493.
38. Batrakova E., Lee S., Li S., Venne A., Alakhov V., Kabanov A. Fundamental relationships between the composition of pluronic block copolymers and their hypersensitization effect in MDR cancer cells. Pharm. Res. 16:(9):1999;1373-1379.
39. Batrakova E.V., Han H.Y., Alakhov V.Yu., Miller D.W., Kabanov A.V. Effects of pluronic block copolymers on drug absorption in Caco-2 cell monolayers. Pharm. Res. 15:(6):1998;850-855.
40. Alakhov V., Klinski E., Li S., Pietrzynski G., Venne A., Batrakova E., Bronitch T., Kabanov A. Block copolymer-based formulation of doxorubicin. From cell screen to clinical trials. Colloids Surf. B Biointerfaces. 16:1999;113-134.
41. Kozlov M.Yu., Melik-Nubarov N.S., Batrakova E.V., Kabanov A.V. Relationship between Pluronic block copolymer structure, critical micellization concentration and partitioning coefficients of low molecular mass solutes. Macromolecules. 33:(9):2000;3305-3313.
42. Pade V., Stavchansky S. Link between drug absorption solubility and permeability measurements in Caco-2 cells. Pharm. Res. 14:1997;1210-1215.
43. Mossman T.J. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods. 65:1983;55-63.
44. Chapter 51 Bromberg L. Biomedical applications of hydrophobically modified polyelectrolytes and polyelectrolyte block-copolymers. Tripathy S., Kumar J., Nalwa H.S. Handbook of Polyelectrolytes and Their Applications. Vol. 1:2002;American Scientific Publishers, Stevenson Ranch, CA.
45. Muranishi M. Absorption enhancers. Crit. Rev. Ther. Drug Carrier Syst. 7:1990;1-33.
46. Batrakova E.V., Han H.-Y., Miller D.W., Kabanov A.V. Effects of pluronic P85 unimers and micelles on drug permeability in polarized BBMEC and Caco-2 cells. Pharm. Res. 15:(10):1998;1525-1532.
47. Tomita M., Hyashi M., Horie T., Ishizawa T., Awazu S. Enhancement of colonic drug absorption by the transcellular permeation route. Pharm. Res. 5:1988;786-789.
48. Tomita M., Hayashi M., Awazu S. Absorption-enhancing mechanism of sodium caprate and decanoylcarnitine in Caco-2 cells. J. Pharmacol. Exp. Ther. 272:1995;739-743.
49. Takahashi H., Shibasaki T., Takeshita K., Kaiho F., Hayashi M. The enhancing mechanism of capric acid (C10) from a suppository on rectal drug absorption through a paracellular pathway. Biol. Pharm. Bull. 20:1997;446-448.
50. Lueßen H.L., Lehr C.-M., Rentel C.-O., Noach A.B.J., de Boer A.G., Verhoef J.C., Junginger H.E. Bioadhesive polymers for the peroral delivery of peptide drugs. J. Controlled Release. 29:1994;329-338.
51. Lueßen H.L., Rentel C.-O., Kotze A.F., Lehr C.-M., de Boer A.G., Verhoef J.C., Junginger H.E. Mucoadhesive polymers in peroral peptide drug delivery. IV. Polycarbophil and chitosan are potent enhancers of peptide transport across intestinal mucosae in vitro. J. Controlled Release. 45:1997;15-23.
52. Bromberg L. Interactions among proteins and hydrophobically modified polyelectrolytes. J. Pharm. Pharmacol. 53:2001;541-547.
53. Artursson P. Epithelial transport of drugs in cell culture: a model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells. J. Pharm. Sci. 79:1990;476-482.
54. Singla A.K., Chawla M., Singh A. Potential applications of carbomer in oral mucoadhesive controlled drug delivery system: a review. Drug Dev. Ind. Pharm. 26:(9):2000;913-924.
55. Russo L.I., Ghaly E.S. Drug release from Carbomer 934 matrices. P.R. Health Sci. J. 19:(2):2000;131-137.
56. Liu P., Davis P., Liu H., Krishnan T.R. Evaluation of cytotoxicity and absorption enhancing effects of melittin - a novel absorption enhancer. Eur. J. Pharm. Biopharm. 48:1999;85-87.
57. 14C-labelled poly(acrylic acids): an in vivo study. Biomaterials. 22:(13):2001;1861-1867.
58. 14C-labelled poly(acrylic acid) dispersions. Int. J. Pharm. 236:(1-2):2002;87-96.